ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Synthetic Biology

Bright Peak launches for synthetic proteins

by Lisa M. Jarvis
July 31, 2020 | APPEARED IN VOLUME 98, ISSUE 30

 

Bright Peak Therapeutics has emerged from stealth with $35 million to develop synthetic protein therapeutics. The firm’s first project is an improved version of interleukin-2, a cytokine that is being hotly pursued as a cancer immunotherapy. Based in Switzerland, Bright Peak was incubated and backed by the investment firmVersant Ventures. It’s based on technology developed by ETH Zurich organic chemist Jeffrey Bode, who came up with a simple way to stitch together amino acid sequences.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment